GlobeNewswire: Oryzon Genomics Contains the last 10 of 17 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T12:31:31ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/02/15/1726292/0/en/ORYZON-Reports-Financial-Results-and-Corporate-Update-for-the-4th-Quarter-and-Year-Ended-December-31-2018.html?f=22&fvtc=4&fvtv=47821ORYZON Reports Financial Results and Corporate Update for the 4th Quarter and Year Ended December 31, 20182019-02-15T16:41:03Z<![CDATA[-$0.04/share for the 12 months ended December 31st]]>https://www.globenewswire.com/news-release/2019/02/06/1711375/0/en/ORYZON-Announces-Publication-of-a-relevant-paper-for-the-therapeutic-development-of-Iadademstat-ORY-1001-in-Small-Cell-Lung-Cancer-SCLC.html?f=22&fvtc=4&fvtv=47821ORYZON Announces Publication of a relevant paper for the therapeutic development of Iadademstat (ORY-1001) in Small Cell Lung Cancer (SCLC)2019-02-06T13:00:00Z<![CDATA[MADRID, Spain and CAMBRIDGE, Mass., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the publication by US scientists of a new paper in the February issue of Science Signaling, from the SCIENCE group (AAAS) describing how ORY-1001 (iadademstat) activates the NOTCH pathway, resulting in the repression of SCLC tumorigenesis in vitro and in patient-derived xenograft (PDX) models.]]>https://www.globenewswire.com/news-release/2019/01/29/1706776/0/en/Oryzon-to-present-at-upcoming-international-conferences.html?f=22&fvtc=4&fvtv=47821Oryzon to present at upcoming international conferences2019-01-29T13:00:00Z<![CDATA[MADRID, Spain and CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the company will continue its institutional presence in several reputed international conferences in the upcoming weeks.]]>https://www.globenewswire.com/news-release/2018/12/17/1668216/0/en/Oryzon-to-join-the-IBEX-Small-Cap-Index.html?f=22&fvtc=4&fvtv=47821Oryzon to join the IBEX Small Cap Index2018-12-17T17:32:47Z<![CDATA[The inclusion will become effective on December 24th]]>https://www.globenewswire.com/news-release/2018/11/02/1641994/0/en/ORYZON-Reports-Financial-Results-and-Corporate-Update-for-the-3rd-Quarter-Ended-September-30-2018.html?f=22&fvtc=4&fvtv=47821ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 20182018-11-02T12:00:00Z<![CDATA[-$0.01/share for the 9 months ended September 30th]]>https://www.globenewswire.com/news-release/2018/10/17/1622568/0/en/ORYZON-receives-approval-to-start-CLEPSIDRA-a-Phase-IIa-clinical-trial-in-Small-Cell-Lung-Cancer-with-Iadademstat-ORY-1001.html?f=22&fvtc=4&fvtv=47821ORYZON receives approval to start CLEPSIDRA: a Phase IIa clinical trial in Small Cell Lung Cancer with Iadademstat (ORY-1001)2018-10-17T12:00:00Z<![CDATA[MADRID, Spain and CAMBRIDGE, Mass., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), (“Oryzon”), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today that it has received approval of a Clinical Trial Application (CTA), the European IND equivalent, from the Spanish Drug Agency (AEMPS) to conduct a Phase IIa clinical study with Iadademstat (ORY-1001) in Small Cell Lung Cancer (SCLC) patients in first relapse.]]>https://www.globenewswire.com/news-release/2018/10/09/1618436/0/en/Oryzon-announces-first-patient-enrolled-in-REIMAGINE-a-Phase-IIa-clinical-trial-with-Vafidemstat-ORY-2001-in-aggressiveness.html?f=22&fvtc=4&fvtv=47821Oryzon announces first patient enrolled in REIMAGINE: a Phase IIa clinical trial with Vafidemstat (ORY-2001) in aggressiveness2018-10-09T12:00:00Z<![CDATA[MADRID, Spain and CAMBRIDGE, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), (“Oryzon”), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today that the first patient has been enrolled in the REIMAGINE Phase IIa trial with Vafidemstat (ORY-2001) in patients with episodes of aggressiveness.]]>https://www.globenewswire.com/news-release/2018/09/21/1574271/0/en/September-21st-World-Alzheimer-s-Day-around-the-world.html?f=22&fvtc=4&fvtv=47821September 21st: World Alzheimer’s Day around the world2018-09-21T12:00:00Z<![CDATA[MADRID, Spain and CAMBRIDGE, Mass., Sept. 21, 2018 (GLOBE NEWSWIRE) -- Oryzon Genomics, its scientists and staff want today to join the international chorus of voices to raise awareness of this disease that affects millions of people. Dementia affects over 50 million people worldwide, stealing patients slowly but progressively their memories, skills and behavioural awareness. While there are over 100 forms of dementia, the most common is Alzheimer’s Disease (AD) accounting for 50-60% of all dementia cases.]]>https://www.globenewswire.com/news-release/2018/09/11/1569081/0/en/ORYZON-receives-approval-to-start-ALICE-a-Phase-IIa-clinical-trial-in-AML-with-Iadademstat-ORY-1001.html?f=22&fvtc=4&fvtv=47821ORYZON receives approval to start ALICE: a Phase IIa clinical trial in AML with Iadademstat (ORY-1001)2018-09-11T12:00:00Z<![CDATA[MADRID, Spain and CAMBRIDGE, Mass., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today that it has received approval of a Clinical Trial Application (CTA), the European IND equivalent, from the Spanish Drug Agency (AEMPS) to conduct a Phase IIa clinical study with Iadademstat (ORY-1001) in elderly Acute Myeloid Leukemia (AML) patients not eligible for intensive chemotherapy.]]>https://www.globenewswire.com/news-release/2018/09/07/1567968/0/en/Oryzon-receives-approval-to-begin-REIMAGINE-a-Phase-IIa-clinical-trial-with-Vafidemstat-ORY-2001-in-aggressiveness.html?f=22&fvtc=4&fvtv=47821Oryzon receives approval to begin REIMAGINE: a Phase IIa clinical trial with Vafidemstat (ORY-2001) in aggressiveness2018-09-07T12:40:03Z<![CDATA[MADRID, Spain and CAMBRIDGE, Mass., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today the approval by the Spanish Medicines Agency (AEMPS) of a clinical trial authorization (CTA) to carry out a Phase IIa trial with Vafidemstat (ORY-2001) in patients with episodes of aggressiveness.]]>